Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2144557 | Lung Cancer | 2006 | 9 Pages |
Abstract
When administered in combination with etoposide and carboplatin, paclitaxel is able to offer in SCLC patients with extensive disease a survival benefit without additional toxicities, but with gains in patient-reported quality of life. In terms of efficient palliative care, TEC might be seen as an alternative to standard cisplatin plus etoposide in patients requesting a powerful palliative regimen not compromising any survival benefit.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Martin Reck, Joachim von Pawel, Hans-Nicholas Macha, Eckhard Kaukel, Karl-Matthias Deppermann, Reiner Bonnet, Kurt Ulm, Sybill Hessler, Ulrich Gatzemeier,